Drug Topics

OCTOBER 1, 2022

The move is meant to expand access to reproductive health care for women in the state.

469

469

PhRMA

OCTOBER 1, 2022

A recent report from the Initiative for Medicines, Access & Knowledge – known as I-MAK – highlights fundamental misunderstandings about America’s patent system and how it benefits patients and medical innovation. I-MAK accuses biopharmaceutical companies of blocking competition and gaming the system by patenting new innovations, when in reality, new patents do not extend old patents, and they do not prevent competitors from launching new products.

263

263

Drug Topics

OCTOBER 1, 2022

Take in these top tips for pharmacy front-end management.

469

469

Pharmacy Times

OCTOBER 1, 2022

This month's generic product news features clorazepate dipotassium tablets, exemestane tablets, and paliperidone extended-release tablets.

149

149

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

OCTOBER 1, 2022

MyRx AI Pricing uses enhanced analytics to bring dynamic pricing to pharmacies and cash-paying customers.

465

465

PharmaVoice

OCTOBER 1, 2022

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

147

147

Pharmacy Times

OCTOBER 1, 2022

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

129

129

Drug Topics

OCTOBER 1, 2022

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.

FDA 247

FDA 247

Pharmacy Times

OCTOBER 1, 2022

New research in immunotherapy is exploring vaccines to treat cancer, whether preventative or reactive against current tumors.

Vaccines 123

Vaccines 123

Drug Topics

OCTOBER 1, 2022

The new guidance aims to improve supply for harm reduction programs.

FDA 247

FDA 247

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmacy Times

OCTOBER 1, 2022

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

122

122

Drug Topics

OCTOBER 1, 2022

Your weekly roundup of the latest news from Drug Topics®.

247

247

Pharmacy Times

OCTOBER 1, 2022

Willoughby hopes on a global standpoint that every chronic condition patient has access to a support team that is there to provide care.

121

121

European Pharmaceutical Review

OCTOBER 1, 2022

Bioheng Biotech , a biotechnology firm that develops cellular immunotherapies, have issued key Phase I clinical trial (NCT04538599) results for the drug RD13-01, an anti-CD7 universal CAR-T therapy, establishing that it is safe for use and has the potential to eliminate malignant tumours. It is the first trial to use healthy donor-derived CD7-targeting allogeneic CAR T cells to treat CD7-positive haematological tumours.

Chemotherapy 109

Chemotherapy Hospitals 109

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmacy Times

OCTOBER 1, 2022

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

106

106

The Thyroid Pharmacist

OCTOBER 1, 2022

After my own Hashimoto’s diagnosis in 2009, I wanted to figure out what I could do to live the healthiest life possible. I wanted to know if there was anything I could do to address my symptoms and reverse my condition — or at least stop its progression. So, I set out on a journey to find the root cause of my disease. I have learned that Hashimoto’s symptoms result from a combination of thyroid hormone imbalances, nutrient deficiencies, food sensitivities, an impaired ability to handle stress, a

Adverse Reactions 98

Adverse Reactions Insurance Dosage Immunization 98

STAT

OCTOBER 1, 2022

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.  That’s right. Send us your changes, and we’ll find a home for them.   Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

98

98

European Pharmaceutical Review

OCTOBER 1, 2022

The Committee of Ministers for the Council of Europe has adopted a recommendation for Member States to collate use and availability data for tissues and cells, so that immediate provision is granted to end users. Sharing data across borders ensures access to safe tissues and cells for human application is ethical and supply quality is adequate, said the Council in a statement.

Communication 98

Communication 98

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

pharmaphorum

OCTOBER 1, 2022

With Frontiers Health 2022 mere weeks away, we continue to interview members of the steering committee, gaining insight into what to expect from Milan. In this latest coverage, pharmaphorum speaks with Eugene Borukhovich. Formerly global head of digital health at Bayer, these days Borukhovich is travelling the entrepreneurial path, co-founder and COO of YourCoach.Health, together with his wife, Marina, who is also herself a health coach.

Insurance 98

Insurance FDA Hospitals 98

ISPE

OCTOBER 1, 2022

Determine the right dust collection equipment for tablet press applications. Trudy Patterson. Sat, 10/01/2022 - 06:00. White Paper — Sponsored Content. Determine the right dust collection equipment for tablet press applications. 1 October 2022. Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical in achieving the widely held goal of “error-free performance.

Communication 96

Communication 96

The Spirit Pharmacist

OCTOBER 1, 2022

This vlog features a sneak peek at a content module from one of my courses titled ' Breakthrough Psychedelics: MDMA, Psilocybin, and Ketamine ' and is a summary discussion that compares and contrasts the pharmacology and clinical characteristics of MDMA, psilocybin, and ketamine. It's a helpful place to start for a summary narrative of pharmacology and clinical potential of Breakthrough Psychedelics, and I know a lot of you are interested in going deeper and taking your knowledge of these psyche

96

96

European Pharmaceutical Review

OCTOBER 1, 2022

Researchers have shown that nitrogen dioxide (NO 2 ) gas sterilisation may be the most appropriate choice for the sterilisation of intravitreal injections (IVIs) packaged in polymer-based prefilled syringes (P-PFSs). In their work, the team compared the ingression of gas and the resulting physical and chemical degradation to a model protein in formulation, when sterilising with NO 2 , ethylene oxide (EO) and vaporized hydrogen peroxide (VHP).

Packaging 95

Packaging Immunization 95

Pharmacy Times

OCTOBER 1, 2022

Indicated for the management of mild, moderate, and severe Alzheimer disease and dementia symptoms, the donepezil transdermal system (Adlarity; Corium) delivers donepezil hydrocholoride through the skin and is recommended at an initial dosage of 5 mg per day.

Dosage 91

Dosage 91

pharmaphorum

OCTOBER 1, 2022

Intercept Pharma’s hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the company lost around 16% of their value after the top-line result of the REVERSE study in patients with compensated NASH-related cirrhosis were announced, as investors tried to work out what the failure will mean for the drug’s prospects.

FDA 59

FDA 59

Pharmacy Times

OCTOBER 1, 2022

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

81

81

pharmaphorum

OCTOBER 1, 2022

UK digital health company Babylon has hired Andrew Hine to take charge of its international expansion efforts, as it fights to retain its stock market listing in the US. Andrew Hine via LinkedIn. Formerly partner and head of health for Middle East and North Africa (MENA) at accounting group Ernst & Young, Hine will head up Babylon’s go-to-market team for Europe, Middle East, and Africa (EMEA), as well as Asia.

59

59

Pharmacy Times

OCTOBER 1, 2022

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

65

65

Pharma Times

OCTOBER 1, 2022

The research involves patients with advanced solid malignancies on tumour-directed therapy

58

58

Pharmacy Times

OCTOBER 1, 2022

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

65

65

Board Vitals - Pharmacist

OCTOBER 1, 2022

Pediatricians and Pediatric Nurse Practitioners specialize in caring for children from infancy throughout adolescence. While these healthcare professionals both care for children, there are different education requirements and scopes of practice involved. In this article we’ll take a look at some of the key similarities and differences between pediatricians and pediatric nurse practitioners.

Medical Schools 52

Medical Schools Patient Care Insurance Hospitals 52

Pharmacy Times

OCTOBER 1, 2022

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

65

65

ISPE

OCTOBER 1, 2022

Understanding the Deactivation Capabilities of Hydrogen Peroxide: Bacillus Atropheaus vs Geobacillus Stearothermophilus. Trudy Patterson. Sat, 10/01/2022 - 06:00. White Paper — Sponsored Content. Understanding the Deactivation Capabilities of Hydrogen Peroxide: Bacillus Atropheaus vs Geobacillus Stearothermophilus. 1 October 2022. This article analyzes the hydrogen peroxide deactivation kinetics of representative bioburden in the pharmaceutical, healthcare and food industries, as well as the rol

Communication 52

Communication 52

Pharmacy Times

OCTOBER 1, 2022

Douglas Hoey, CEO of NCPA, discusses NCPA's Annual Convention 2022, which will be held in Kansas City, Missouri from October 1 to October 4.

65

65